Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins (Q34310282)

1 August 2017

1 reference

title

Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins (English)

1 reference

1 August 2017

1 reference

1 reference

Papadakis JA

1

1 reference

1 August 2017

Milionis HJ

series ordinal

2

1 reference

1 August 2017

Press M

series ordinal

3

1 reference

1 August 2017

Mikhailidis DP

series ordinal

4

1 reference

1 August 2017

1 July 2001

1 reference

Journal of Diabetes and its Complications

1 August 2017

1 reference

1 August 2017

15

1 reference

1 August 2017

4

1 reference

1 August 2017

211-226

1 reference

Effect of diabetes mellitus on formation of coronary collateral vessels

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Management of dyslipidemia in adults with diabetes. American Diabetes Association

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Pravastatin Multinational Study Group for Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Risk stratification in coronary artery disease and special populations

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Beneficial effect of short-term endurance training on glucose metabolism during rehabilitation after coronary bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Vascular disease and lipids in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Treatment of diabetic dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Management of dyslipidemia in adults with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Prognosis in diabetics with chest pain or other symptoms suggestive of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Sex differences in coronary mortality among diabetics in Evans County, Georgia

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effects of caloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

A multi-centre study of the efficacy and safety of pravastatin in hypercholesterolaemic patients with non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effects of lovastatin in diabetic patients treated with chlorpropamide

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Long-term efficacy and tolerability of pravastatin in hypercholesterolemia in patients with non-insulin-dependent diabetes mellitus. Hyogo Pravastatin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Long-term effects of simvastatin in hypercholesterolemic patients with NIDDM and additional atherosclerotic risk factors. Hyogo Simvastatin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

The effect of intensive dietary therapy on serum high density lipoprotein cholesterol in patients with Type 2 (non-insulin-dependent) diabetes mellitus: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Inter-relationship between insulin secretion and plasma free fatty acid and triglyceride transport kinetics in maturity onset diabetes and the effect of phenethylbiguanide (phenformin)

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Dyslipidemia, morbidity, and mortality in non-insulin-dependent diabetes mellitus. Lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Does NIDDM increase the risk for coronary heart disease similarly in both low- and high-risk populations?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effect of atorvastatin on low-density lipoprotein subfraction profile

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Myocardial infarction in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Cerebrovascular disorders in patients with diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Clinical features of unrecognized myocardial infarction--silent and symptomatic. Eighteen year follow-up: the Framingham study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution. Results from the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Platelet function and lipid-lowering interventions

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Lipids and stroke: neglect of a useful preventive measure?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes? Need for trial evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Role of fibrates in the management of hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

High-density and low-density lipoproteins and prevalence of vascular disease in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Pravastatin in diabetes-associated hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Prognosis of patients with diabetes mellitus after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

1 reference

7 January 2021

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Comparison of statins in hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Does glycemic control of type II diabetes suffice to control diabetic dyslipidemia? A community perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. NIDDM Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

The evolving role of statins in the management of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: the Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900139-8

7 January 2021

10.1016/S1056-8727(01)00139-8

Identifiers

DOI

1 reference

release_nexlv2gyybf7pidri6g5akwuyi

1 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nexlv2gyybf7pidri6g5akwuyi

24 November 2022

mapped directly with Wikidata item

1 reference